Baillie Gifford & CO Guardant Health, Inc. Transaction History
Baillie Gifford & CO
- $126 Billion
- Q1 2024
A detailed history of Baillie Gifford & CO transactions in Guardant Health, Inc. stock. As of the latest transaction made, Baillie Gifford & CO holds 6,232,104 shares of GH stock, worth $169 Million. This represents 0.1% of its overall portfolio holdings.
Number of Shares
6,232,104
Previous 6,178,812
0.86%
Holding current value
$169 Million
Previous $167 Million
23.08%
% of portfolio
0.1%
Previous 0.14%
Shares
2 transactions
Others Institutions Holding GH
# of Institutions
309Shares Held
110MCall Options Held
2.51MPut Options Held
1.7M-
Vanguard Group Inc Valley Forge, PA11.4MShares$310 Million0.0% of portfolio
-
Black Rock Inc. New York, NY11MShares$298 Million0.01% of portfolio
-
Deep Track Capital, LP Greenwich, CT6MShares$163 Million4.09% of portfolio
-
Cadian Capital Management, LP New York, NY5.79MShares$157 Million4.28% of portfolio
-
Eventide Asset Management, LLC Boston, MA4.18MShares$113 Million1.39% of portfolio
About Guardant Health, Inc.
- Ticker GH
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 102,220,000
- Market Cap $2.77B
- Description
- Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a cl...